D-guluronic acid | 15769-56-9

• 物质功能分类: 生物化工 - 生化试剂
• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: D-guluronic acid
• 英文别名: guluronic acid；D-guluronic acid；L-Guluronsaeure；Guluronsaeure；(2S,3R,4R,5R)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid
• CAS: 15769-56-9
• 化学式: C₆H₁₀O₇
• 分子量: 194.141
• InChiKey: IAJILQKETJEXLJ-KLVWXMOXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.6
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  135
• 氢给体数：
  5
• 氢受体数：
  7

制备方法与用途

Guluronic acid（G2013）是透明质酸的一种有机成分，它不仅是一种非甾体抗炎药，还表现出良好的抗炎效果。

反应信息

• 作为产物：
  描述：

  L-(-)-葡萄糖 在 1 wt% Au/TiO₂ 、 platinum embedded nanoporous carbon 、 氧气 作用下， 以 水 为溶剂， 60.0~89.0 ℃ 、5.27 MPa 条件下， 反应 64.0h， 生成 glucaric acid 、 D-guluronic acid
  参考文献：
  名称：

  [EN] PROCESSES FOR PREPARING ALDARIC, ALDONIC, AND URONIC ACIDS
  [FR] PROCÉDÉS DE PRÉPARATION D'ACIDES ALDARIQUES, ALDONIQUES ET URONIQUES

  摘要：

  描述了制备阿尔达酸、醛酸、糖醛酸和/或内酯的各种工艺。例如，描述了通过催化氧化C2-C7醛酸和/或内酯以及/或C2-C7醛糖制备C2-C7阿尔达酸和/或内酯的工艺。

  公开号：

  WO2021101810A1

文献信息

• CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS
  申请人：Bapat Abhijit S.

  公开号：US20140364595A1

  公开（公告）日：2014-12-11

  The invention provides conjugate-based antifungal or antibacterial prodrugs formed by coupling at least one anti-fungal agent or antibacterial agent with at least one linker and/or carrier. The prodrugs are of formula: (i) (AFA) m -X-(L) n ; (ii) [(AFA) m′ -X] p -L; (iii) AFA-[X-(L) n′ ] q ; or (iv) (AFA) m″ -X, wherein: AFA is an antifungal agent or an antibacterial agent; L is a carrier; X is a linker; m ranges from 1 to 10; n ranges from 2 to 10; m′ is 1 to 10; p is 1 to 10; n′ is 1 to 10; and q is 1 to 10, provided that q′ and n are not both 1; and m″ is 1 to 10. The invention also provides nanoparticles comprising the conjugate-based prodrugs. Additionally, the invention also provides non-conjugated antifungal and antibacterial agents in the form of nanoparticles.

  该发明提供了由至少一种抗真菌剂或抗菌剂与至少一种连接剂和/或载体偶联形成的基于共轭的抗真菌或抗菌前药。这些前药的公式为：(i) (AFA) m -X-(L) n ; (ii) [(AFA) m′ -X] p -L; (iii) AFA-[X-(L) n′ ] q ; 或 (iv) (AFA) m″ -X，其中：AFA是抗真菌剂或抗菌剂；L是载体；X是连接剂；m范围从1到10；n范围从2到10；m′为1到10；p为1到10；n′为1到10；q为1到10，前提是q'和n不同时为1；m″为1到10。该发明还提供了包含基于共轭的前药的纳米粒子。此外，该发明还提供了以纳米粒子形式的非共轭抗真菌和抗菌剂。
• [EN] COMPOSITIONS AND METHODS THEREOF<br/>[FR] COMPOSITIONS ET PROCÉDÉS ASSOCIÉS
  申请人：EXCIVA UG HAFTUNGSBESCHRAENKT

  公开号：WO2018039642A1

  公开（公告）日：2018-03-01

  Compounds of formula I, (I) or enantiomers thereof, metabolites thereof, derivatives thereof, deuterated derivatives thereof, halogenated derivatives thereof, prodrugs thereof, pharmaceutically acceptable salts thereof, N- oxides thereof, or a combination thereof, processes and intermediates for preparation thereof, compositions thereof, and uses thereof, are provided. Pharmaceutical compositions comprising a compound of formula I and a compound of Formula II: (IIa) (IIb) or enantiomers thereof, metabolites thereof, derivatives thereof, deuterated derivatives thereof, prodrugs thereof, pharmaceutically acceptable salts thereof, N-oxides thereof, or a combination thereof. Compositions and methods for improving the efficacy of DEX, or providing beneficial pharmacokinetic effects to DEX, comprising co-administering a compound of formula I or SARPO, and a compound of Formula II or DEX to a subject in need thereof, and dosage forms, drug delivery systems, methods of treatment thereof.

  提供具有公式I的化合物(I)或其对应异构体、代谢物、衍生物、氘化衍生物、卤化衍生物、前药、药用可接受盐、N-氧化物或其组合，以及它们的制备过程和中间体、组合物和使用方法。包含公式I化合物的药物组合物以及公式II的化合物(IIa) (IIb)或其对应异构体、代谢物、衍生物、氘化衍生物、前药、药用可接受盐、N-氧化物或其组合。包含共给予需要该物质的受试者公式I化合物或SARPO和公式II化合物或DEX的DEX效能改进或提供DEX有益药代动力学效果的组合物和方法，以及剂量形式、药物传递系统、治疗方法。
• [EN] POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE<br/>[FR] PROMÉDICAMENTS D'OPIOÏDES À SOUS-UNITÉS MULTIPLES RÉSISTANTS AUX SURDOSES ET AUX ABUS
  申请人：ELYSIUM THERAPEUTICS INC

  公开号：WO2018170465A1

  公开（公告）日：2018-09-20

  The invention provides compositions and methods for the treatment or prevention of pain. Compositions provided are resistant to overdose and abuse. Compositions provided comprise two or more different molecules, where each molecule comprises at least one GI enzyme-labile opioid agonist releasing subunit comprising an opioid agonist that is covalently linked to at least one GI enzyme inhibitor subunit.

  这项发明提供了用于治疗或预防疼痛的组合物和方法。所提供的组合物具有抗过量和滥用的特性。所提供的组合物包括两种或两种以上不同的分子，其中每种分子至少包括一个至少含有一个胃肠酶敏感的阿片类受体激动剂释放亚基的阿片类受体激动剂，该阿片类受体激动剂与至少一个胃肠酶抑制剂亚基共价连接。
• POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE
  申请人：Elysium Therapeutics, Inc.

  公开号：US20170100390A1

  公开（公告）日：2017-04-13

  The invention provides compositions and methods for the treatment or prevention of pain. The invention provides constructs whereby hydrolysis of the construct by a specified gastrointestinal enzyme directly, or indirectly, releases an opioid when taken orally as prescribed. The gastrointestinal enzyme mediated release of opioid from constructs of the invention is designed to be attenuated in vivo via a saturation or inhibition mechanism when overdoses are ingested. The invention further provides constructs that are highly resistant to oral overdose, chemical tampering, and abuse via non-oral routes of administration.

  这项发明提供了用于治疗或预防疼痛的组合物和方法。该发明提供了构造物，通过指定的胃肠酶在口服时直接或间接地水解构造物释放阿片类物质。该发明中构造物中的胃肠酶介导的阿片类物质释放被设计为在体内通过饱和或抑制机制在摄入过量时减弱。该发明进一步提供了对口服过量、化学篡改和通过非口服途径滥用高度抵抗的构造物。
• [EN] PHARMACEUTICAL COMPOSITIONS<br/>[FR] COMPOSITIONS PHARMACEUTIQUES
  申请人：GENZYME CORP

  公开号：WO2009154747A1

  公开（公告）日：2009-12-23

  This invention relates to crosslinked amine-containing polymers for binding compounds or ions, and more specifically relates to pharmaceutically acceptable compositions for binding compounds or ions that include crosslinked amine-containing polymers. The pharmaceutically acceptable composition includes, for example, crosslinked polyamine particles, or pharmaceutically acceptable salts thereof, having a particle size distribution wherein greater than 10 vol.% of the particles have a particle size greater than 500 μm.

  这项发明涉及交联胺含有聚合物用于结合化合物或离子，更具体地涉及用于结合化合物或离子的药用可接受组合物，其中包括交联胺含有聚合物。药用可接受组合物包括例如交联聚胺颗粒或其药用可接受盐，具有粒径分布，其中大于10体积%的颗粒具有大于500μm的粒径。